Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 6/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4706617 | 0.85 | NPC1 (0.59) | MAOBNPC1RAB9ATDP1APP | |
| SCHEMBL4829846 | 0.85 | BACE1 (0.54) | MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL825091 | 0.82 | ERN1 (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL20094475 | 0.79 | NPC1 (0.49) | MAOBNPC1RAB9ATDP1APP | |
| SCHEMBL25173929 | 0.78 | MAOB (0.55) | MAOBNPC1RAB9ATDP1APP | |
| SCHEMBL2605834 | 0.78 | BACE1 (0.34) | SMN1; SMN2ALDH1A1TP53CYP3A4ALOX15 | |
| SCHEMBL16310074 | 0.78 | NQO1 (0.45) | NPC1RAB9ATDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL190181 | 0.75 | MAOB (0.55) | MAOBNPC1RAB9ATDP1APP | |
| SCHEMBL4705322 | 0.75 | MAOB (0.51) | MAOBNPC1RAB9ATDP1APP | |
| SCHEMBL21244006 | 0.74 | APP (0.61) | MAOBNPC1RAB9ATDP1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673424-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4489855-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024182268-A1 | LIQUID PHASE PEPTIDE SUPPORT SYNTHESIS OF PEPTIDES AND PEPTIDOMIMETICS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116615251-A | Antibody-drug conjugates comprising GLP1 peptide mimetics and the uses thereof | 瑞泽恩制药公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4210767-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2022056494-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096648-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | MAOB 4767/4885NPC1 2674/4885RAB9A 983/4885 |
| US-20250161476-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | MAOB 4767/4885NPC1 2674/4885RAB9A 983/4885 |
| US-12280124-B2 | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof | GLP1R, GIPR, GCGR | MAOB 4767/4885NPC1 2674/4885RAB9A 983/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | MAOB 4719/4885NPC1 1547/4885RAB9A 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.